The variable domains tend to have relatively long antigen-binding loops and because the light chain present in human antibodies is not in the way, they are ideally suited for reaching epitopes residing in clefts or pockets. 1 is for use against a microbial pathogen, respiratory syncytial computer virus (RSV). The rest are for autoimmune diseases, malignancy, asthma, or angioedema. Palivizumab is a humanized immunoglobin G1 (IgG1) mAb derived from the original murine mAb 1129 [1], and is licensed for the prophylactic treatment of premature infants to prevent severe disease from RSV [2]. Palivizumab and its higher-affinity derivative, motavizumab, recognize an epitope in the RSV fusion (F) glycoprotein (antigenic site II) and the atomic structure of the interaction has been characterized [3]. In this issue of theJournal of Infectious Diseases, Schepens et Hexachlorophene al. have reported the development of Nanobodies (Ablynx) specific for the palivizumab epitope and have evaluated their potency in vivo in a murine model [4]. Nanobodies are proteins representing the variable domain of the heavy chain from antibodies produced by members of the familyCamelidae(camels, llamas, and alpacas). Cartilaginous fish (eg, sharks, skates, and rays) and camelids have uniquely developed heavy-chain-only immunoglobulin molecules that recognize and bind antigenic sites with just the single variable domain at the tip of the heavy chain. The basis for this adaptation is usually unknown, but there is evidence of convergent evolution [5]. The variable domains tend to have relatively long antigen-binding loops and because the light chain present in human antibodies is not in the way, they are ideally suited for reaching epitopes residing in clefts or pockets. For example, llama-derived heavy-chain variable domains (VHH) have been discovered that can reach into the CD4 binding pocket of human immunodeficiency computer virus (HIV) gp120, resulting in broad neutralizing activity [6]. Heavy-chain-only antibodies tend to have more charged and polar residues in the framework 2 region of the variable domain name, which in classic human immunoglobulins, has highly conserved hydrophobic sequences that are adjacent to the light chain. The VHH also has a relatively high frequency of cysteine residues that allow intradomain disulfide bonds, and together with the polar interactions between loops help to stabilize the antigen-binding sites, perhaps to compensate for the lost stabilizing effect of a light chain [5,6]. The investigators immunized llamas with a trimeric transmembrane-deleted form of the F glycoprotein, and then cloned VHH sequences into a phagemid vector. The resulting phage library was screened for binding to F, and sequences were identified that competed for binding with palivizumab. Microneutralization assays against the RSV Long strain (a prototypic subtype A laboratory-adapted isolate) showed that this monovalent VHH-designated RSV-D3 is about 3-fold more potent than the palivizumab antigen-binding fragment (Fab). Interestingly, Rabbit Polyclonal to Amyloid beta A4 (phospho-Thr743/668) a bivalent version of RSV-D3 made with Gly-Ser Hexachlorophene linkers is about 40-fold more potent than the bivalent palivizumab mAb. One of the important characteristics of palivizumab is usually that it is equally potent against subtype B RSV strains. Surprisingly, the bivalent RSV-D3 was about 600-fold less potent against the RSV B1 strain than it was against the subtype A computer virus [7]. The reason for the difference in cross-reactivity is usually intriguing because neutralization escape mutations for palivizumab also escape RSV-D3, suggesting similar contact residues. It may be related to the size of the interaction area, or it is possible that this VHH is usually a relatively rigid, preorganized structure that gives it higher affinity, but makes it less flexible for adjusting to minor variations in epitope structure. Defining the crystal structure of the interaction may be informative for understanding cross-neutralization Hexachlorophene and other fundamental aspects of viral neutralization. It may also provide insight as to why the structurally conserved, scaffolded palivizumab epitope can elicit antibodies that bind F, but do not neutralize RSV [8]. The RSV-D3 bivalent Nanobody neutralizes by inhibiting fusion and not by blocking attachment. This is also Hexachlorophene true for palivizumab and motavizumab, so it is not surprising. The epitope appears to be present throughout the fusion process, based on modeling of the prefusion F trimer and structure of the postfusion trimer [9]. The assumption based on structural analysis is that palivizumab and motavizumab inhibit fusion by binding a prehairpin fusion intermediate structure, thereby interfering with formation of the final 6-helix bundle that pulls the computer virus and target cell membranes.